Literature DB >> 27794415

Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.

Yuzo Suzuki1, Tatsuro Okamoto2, Takatoshi Fujishita1, Masakazu Katsura1, Takaki Akamine1, Shinkichi Takamori1, Yosuke Morodomi1, Tetsuzo Tagawa1, Fumihiro Shoji1, Yoshihiko Maehara1.   

Abstract

OBJECTIVES: Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass and strength. We aimed to investigate sarcopenia in patients with stage I non-small cell lung cancer (NSCLC) who underwent complete resection, and the relationship of sarcopenia with clinicopathological factors.
METHODS: All consecutive patients who underwent lung resection between January 2005 and December 2008 were enrolled in this retrospective study. Eligible patients were assigned to one of 2 groups according to the presence or absence of sarcopenia, as assessed by the sum of cross-sectional areas of skeletal muscles in the region of the third lumbar vertebra (L3) on preoperative computed tomography (CT).
RESULTS: Sixteen of 52 male (30.8%) and 22 of 38 female (57.9%) patients were identified with sarcopenia (p=0.01). Patients with sarcopenia were more likely to have a low body mass index (BMI) (p<0.0001). Kaplan-Meier analysis showed that patients with sarcopenia had a significantly worse outcome than patients without sarcopenia (5-year-survival: 72.8% vs 85.8%, respectively, p=0.028). Multivariate analysis found that sarcopenia was a significant independent prognostic factor (hazard ratio: 7.09, p=0.0008).
CONCLUSIONS: Sarcopenia identified on a cross-sectional CT image of the L3 level was associated with poor outcome with completely resected early-stage NSCLC.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Computed tomography; Non-small cell lung cancer; Prognosis; Sarcopenia

Mesh:

Year:  2016        PMID: 27794415     DOI: 10.1016/j.lungcan.2016.08.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  36 in total

1.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.

Authors:  M D Goncalves; S Taylor; D F Halpenny; E Schwitzer; S Gandelman; J Jackson; A Lukose; A J Plodkowski; K S Tan; M Dunphy; L W Jones; R J Downey
Journal:  Clin Radiol       Date:  2018-01-06       Impact factor: 2.350

2.  Nutritional support for cancer patients: still a neglected right?

Authors:  Riccardo Caccialanza; Francesco De Lorenzo; Luca Gianotti; Vittorina Zagonel; Cecilia Gavazzi; Gabriella Farina; Paolo Cotogni; Saverio Cinieri; Emanuele Cereda; Paolo Marchetti; Mariateresa Nardi; Elisabetta Iannelli; Claudia Santangelo; Francesca Traclò; Carmine Pinto; Paolo Pedrazzoli
Journal:  Support Care Cancer       Date:  2017-07-14       Impact factor: 3.603

3.  Sarcopenia in resected non-small cell lung cancer: let's move to patient-directed strategies.

Authors:  Philippe Icard; Antonio Iannelli; Hubert Lincet; Marco Alifano
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Editorial: refining the estimation of fitness for surgery.

Authors:  Brienne Ryan; Mark Hennon; Sai Yendamuri
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

5.  Loss of skeletal muscle mass after curative gastrectomy is a poor prognostic factor.

Authors:  Naruji Kugimiya; Eijiro Harada; Kazuhito Oka; Daichi Kawamura; Yuki Suehiro; Yoshihiro Takemoto; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

6.  Sarcopenia predicts poor postoperative outcome in elderly patients with lung cancer.

Authors:  Yo Kawaguchi; Jun Hanaoka; Yasuhiko Ohshio; Keigo Okamoto; Ryosuke Kaku; Kazuki Hayashi; Takuya Shiratori; Makoto Yoden
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-04-10

7.  Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium.

Authors:  Daniel Shepshelovich; Wei Xu; Lin Lu; Aline Fares; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Xifeng Wu; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; M Catherine Brown; Geoffrey Liu; Rayjean J Hung
Journal:  J Thorac Oncol       Date:  2019-06-01       Impact factor: 15.609

8.  Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer.

Authors:  Kuniaki Katsui; Takeshi Ogata; Kenta Watanabe; Kotaro Yoshio; Masahiro Kuroda; Masaomi Yamane; Takao Hiraki; Katsuyuki Kiura; Shinichi Toyooka; Susumu Kanazawa
Journal:  Int J Clin Oncol       Date:  2021-04-20       Impact factor: 3.402

9.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

10.  Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).

Authors:  Alejandro Recio-Boiles; Jose N Galeas; Bernard Goldwasser; Karla Sanchez; Louise M W Man; Ryan D Gentzler; Jane Gildersleeve; Patricia J Hollen; Richard J Gralla
Journal:  Support Care Cancer       Date:  2018-02-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.